{
    "root": "3126d248-b8dc-4225-a886-bd8bed04de5b",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Verzenio",
    "value": "20250227",
    "ingredients": [
        {
            "name": "abemaciclib",
            "code": "60UAB198HK"
        },
        {
            "name": "Microcrystalline Cellulose",
            "code": "OP1R32D61U"
        },
        {
            "name": "Lactose Monohydrate",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "Croscarmellose Sodium",
            "code": "M28OL1HH48"
        },
        {
            "name": "Silicon Dioxide",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "Sodium Stearyl Fumarate",
            "code": "7CV7WJK4UI"
        },
        {
            "name": "Water",
            "code": "059QF0KO0R"
        },
        {
            "name": "Polyvinyl Alcohol, Unspecified",
            "code": "532B59J990"
        },
        {
            "name": "Polyethylene Glycol, Unspecified",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "Titanium Dioxide",
            "code": "15FIX9V2JP"
        },
        {
            "name": "Talc",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "Ferric Oxide Yellow",
            "code": "EX438O2MRT"
        },
        {
            "name": "Ferric Oxide Red",
            "code": "1K09F3G675"
        }
    ],
    "indications": "VERZENIO ® is a kinase inhibitor indicated: in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence. ( 1.1 , 14.1 ) in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. ( 1.2 ) in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. ( 1.2 ) as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. ( 1.2 )",
    "contraindications": "VERZENIO tablets are taken orally with or without food. ( 2.1 ) Recommended starting dose in combination with fulvestrant, tamoxifen, or an aromatase inhibitor: 150 mg twice daily. ( 2.1 ) Recommended starting dose as monotherapy: 200 mg twice daily. ( 2.1 ) Dosing interruption and/or dose reductions may be required based on individual safety and tolerability. ( 2.2 )",
    "warningsAndPrecautions": "How Supplied\n                        \n                        VERZENIO 50 mg tablets are oval beige tablet with “Lilly” debossed on one side and “50” on the other side.\n\n                        VERZENIO 100 mg tablet are oval white to practically white tablet with “Lilly” debossed on one side and “100” on the other side.\n\n                        VERZENIO 150 mg tablets are oval yellow tablet with “Lilly” debossed on one side and “150” on the other side.\n\n                        VERZENIO 200 mg tablets are oval beige tablet with “Lilly” debossed on one side and “200” on the other side.\n\n                        VERZENIO tablets are supplied in 7-day dose pack configurations as follows:\n\n                        \n                           \n                           \n                              \n                                 \n                                    \n                                       200 mg dose pack (14 tablets) – each blister pack contains 14 tablets (200 mg per tablet) (200 mg twice daily)\n\n                                    \n                                 \n                              \n                              \n                                 NDC 0002-6216-54\n\n                              \n                              \n                                 \n                                    \n                                       150 mg dose pack (14 tablets) – each blister pack contains 14 tablets (150 mg per tablet) (150 mg twice daily)\n\n                                    \n                                 \n                              \n                              \n                                 NDC 0002-5337-54\n\n                              \n                              \n                                 \n                                    \n                                       100 mg dose pack (14 tablets) – each blister pack contains 14 tablets (100 mg per tablet) (100 mg twice daily)\n\n                                    \n                                 \n                              \n                              \n                                 NDC 0002-4815-54\n\n                              \n                              \n                                 \n                                    \n                                       50 mg dose pack (14 tablets) – each blister pack contains 14 tablets (50 mg per tablet) (50 mg twice daily)\n\n                                    \n                                 \n                              \n                              \n                                 NDC 0002-4483-54",
    "adverseReactions": "None."
}